Human therapeutic agents
Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.
1. A method of treating a cancer patient comprising the step of administering to the patient a therapeutic anti-cancer composition comprising at least one each of a curcumin a component, a harmine component, and an isovanillin component, where said curcumin component is selected from the group consisting of curcumin, tetrahydro curcumin, demethyl curcumin, demethoxy curcumin, disdemethoxy curcumin, 1,3-diphenyl-2-propanone, caffeic acid phenethyl ester, (1E,4E)-1,5-bis[3,5-bis(methoxymethoxy)phenyl]-1,4-pentadiene-3-one, 1,7-di(1-naphthyl)-2,6-heptanedione, trans,trans-1,5-Bis[4-(trifluoromethyl)phenyl]-1,4-pentadien-3-one, 1,5-dibenzoylpentane, (2E,5E)-2,5-dibenzylidenecyclopentanone, 2,6-bis(4-fluorobenzal)cyclohexanone, (1E,4E)-1,5-bis(4-fluorophenyl)-1,4-pentadien-3-one, FLLL31, and mixtures thereof, said harmine component is selected from the group consisting of harmine, harmaline, harmane, hamalol, harmol, norharmane, 6-methoxyharmalan, bromo harmine, 2-methyl harmine, 4,9-dihydro-3H-beta-carbolin-1-yl methyl ether, 1-(4-nitrophenyl)-2,3,4,9-tetrahydro-1H-beta-carboline hydrochloride, 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole {THbC}, 1,2,3,4-tetrahydro-beta-carboline-1-carboxylic acid, 6-Methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole, 3-hydroxymethyl-b-carboline, 2,3,4,5-tetrahydro-8-methoxy-1H-pyrido[4,3-b]indole, 6-Methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole-1-carboxylic acid, ethyl b-carboline-3-carboxylate, and mixtures thereof, and said isovanillin component is selected from the group consisting of isovanillin, orthovanillin, isovanillyl alcohol, isovanillic acid, 2-bromo-3-hydroxy-4-methoxy benzaldehyde, 2-iodo-3-hydroxy-4-methoxy benzaldehyde, o-anisaldehyde, isovanillin oxime, ethyl vanillin, vanillin isobutyrate, veratraldehyde, 5-nitrovanillin, vanillin acetate, 3-benzyloxy-4-methoxybenzaldehyde, 3-hydroxy-5-methoxybenzaldehyde, methyl isovanillate, acetovanillone (apocynin), 2-hydroxy-4-methoxybenzaldehyde, trans-ferulic acid, 3-hydroxy-4-methoxycinnamic acid, caffeic acid, and mixtures thereof, with the total weight amount of isovanillin component(s) being preponderant, and with the total weight amounts of curcumin component(s) and harmine component(s) being present in lesser amounts, the curcumin, harmine, and isovanillin components being selected and present in amounts to provide anti-cancer synergy for the composition, wherein said cancer is selected from the group consisting of leukemia, lymphoma, ovarian cancer, lung cancer, breast cancer and prostate cancer.
2. The method of claim 1 , wherein said components are individually and independently in the form of esters, metal complexes, pharmaceutically acceptable salts, and mixtures thereof.
3. The method of claim 1 , said composition exhibiting anti-cancer activity against lung cancer cells, lymphoma cells, and leukemia cells.
4. The method of claim 3 , said composition exhibiting anti-cancer activity against lung cancer cells, H358, lymphoma cells, M0205, and leukemia cells, jurkat E6-1.
5. The method of claim 1 , the weight ratios of isovanillin component(s):harmine component(s):curcumin component(s) being approximately 0.1-25:0.1-5:0.1-5.
6. The method of claim 5 , said ratio being about 10:1.7:0.85.
7. The method of claim 1 , wherein said isovanillin component(s) are present at a level of from about 25-85% by weight, said harmine component(s) are present at a level of from about 7-50% by weight, and said curcumin component(s) are present at a level of from about 5-40% by weight, based upon the total weight of the three components taken as 100% by weight.
8. The method of claim 1 , said composition exhibiting anti-cancer synergy with lymphoma, ovarian cancer, or breast cancer cells.
9. The method of claim 8 , said composition exhibiting anti-cancer synergy with lymphoma cancer cells, M0205.
10. The method of claim 8 , said composition exhibiting anti-cancer synergy with ovarian cancer cells, A1847.
11. The method of claim 8 , said composition exhibiting anti-cancer synergy with breast cancer cells, du4475.
12. The method of claim 1 , said composition being in the form of liquids, gels, suspensions, solutions, solids, capsules, pills, or tablets.
13. The method of claim 1 , including the step of administering said composition by oral, rectal, nasal, ophthalmic, parenteral, cutaneous, subcutaneous, or intramuscular administration.
14. A method of inhibiting the growth of cancer cells comprising the step of contacting said cells with an anti-cancer composition comprising at least one each of a curcumin a component, a harmine component, and an isovanillin component, where said curcumin component is selected from the group consisting of curcumin, tetrahydro curcumin, demethyl curcumin, demethoxy curcumin, disdemethoxy curcumin, 1,3-diphenyl-2-propanone, caffeic acid phenethyl ester, (1E,4E)-1,5-bis[3,5-bis(methoxymethoxy)phenyl]-1,4-pentadiene-3-one, 1,7-di(1-naphthyl)-2,6-heptanedione, trans,trans-1,5-Bis[4-(trifluoromethyl)phenyl]-1,4-pentadien-3-one, 1,5-dibenzoylpentane, (2E,5E)-2,5-dibenzylidenecyclopentanone, 2,6-bis(4-fluorobenzal)cyclohexanone, (1E,4E)-1,5-bis(4-fluorophenyl)-1,4-pentadien-3-one, FLLL31, and mixtures thereof, said harmine component is selected from the group consisting of harmine, harmaline, harmane, hamalol, harmol, norharmane, 6-methoxyharmalan, bromo harmine, 2-methyl harmine, 4,9-dihydro-3H-beta-carbolin-1-yl methyl ether, 1-(4-nitrophenyl)-2,3,4,9-tetrahydro-1H-beta-carboline hydrochloride, 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole {THbC}, 1,2,3,4-tetrahydro-beta-carboline-1-carboxylic acid, 6-Methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole, 3-hydroxymethyl-b-carboline, 2,3,4,5-tetrahydro-8-methoxy-1H-pyrido[4,3-b]indole, 6-Methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole-1-carboxylic acid, ethyl b-carboline-3-carboxylate, and mixtures thereof, and said isovanillin component is selected from the group consisting of isovanillin, orthovanillin, isovanillyl alcohol, isovanillic acid, 2-bromo-3-hydroxy-4-methoxy benzaldehyde, 2-iodo-3-hydroxy-4-methoxy benzaldehyde, o-anisaldehyde, isovanillin oxime, ethyl vanillin, vanillin isobutyrate, veratraldehyde, 5-nitrovanillin, vanillin acetate, 3-benzyloxy-4-methoxybenzaldehyde, 3-hydroxy-5-methoxybenzaldehyde, methyl isovanillate, acetovanillone (apocynin), 2-hydroxy-4-methoxybenzaldehyde, trans-ferulic acid, 3-hydroxy-4-methoxycinnamic acid, caffeic acid, and mixtures thereof, with the total weight amount of isovanillin component(s) being preponderant, and with the total weight amounts of curcumin component(s) and harmine component(s) being present in lesser amounts, the curcumin, harmine, and isovanillin components being selected and present in amounts to provide anti-cancer synergy for the composition, wherein said cancer is selected from the group consisting of leukemia, lymphoma, ovarian cancer, lung cancer, breast cancer and prostate cancer.
15. The method of claim 14 wherein said components are individually and independently in the form of esters, metal complexes, pharmaceutically acceptable salts, and mixtures thereof.
16. The method of claim 14 , said composition exhibiting anti-cancer activity against lung cancer cells, lymphoma cells, and leukemia cells.
17. The method of claim 16 , said composition exhibiting anti-cancer activity against lung cancer cells, H358, lymphoma cells, M0205, and leukemia cells, jurkat E6-1.
18. The method of claim 14 , the weight ratios of isovanillin component(s):harmine component(s):curcumin component(s) being approximately 0.1-25:0.1-5:0.1-5.
19. The method of claim 18 , said ratio being about 10:1.7:0.85.
20. The method of claim 14 , wherein said isovanillin component(s) are present at a level of from about 25-85% by weight, said harmine component(s) are present at a level of from about 7-50% by weight, and said curcumin component(s) are present at a level of from about 5-40% by weight, based upon the total weight of the three components taken as 100% by weight.
21. The method of claim 14 , said composition exhibiting anti-cancer synergy with lymphoma, ovarian cancer, or breast cancer cells.
22. The method of claim 21 , said composition exhibiting anti-cancer synergy with lymphoma cancer cells, M0205.
23. The method of claim 21 , said composition exhibiting anti-cancer synergy with ovarian cancer cells, A1847.
24. The method of claim 21 , said composition exhibiting anti-cancer synergy with breast cancer cells, du4475.